Immunostimulant Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Immunostimulant Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2023

Immunostimulants are therapeutic substances that enhance the immune system's response, aiding in the prevention or treatment of various diseases. They work by activating or modulating specific components of the immune system, such as immune cells and cytokines. Immunostimulants can be used in the treatment of infectious diseases, including viral, bacterial, and fungal infections, by boosting the body's natural defense mechanisms. Additionally, they have shown potential in cancer treatment, as they can stimulate the immune system to recognize and eliminate cancer cells. Autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, can also be targeted with immunostimulant therapies to regulate immune responses and restore immune balance. According to WHO, infectious diseases remain a significant global burden, with approximately 17 million deaths reported annually worldwide. In Europe, infectious diseases account for a substantial number of hospital admissions and mortality cases. In the USA, infectious diseases are responsible for millions of healthcare visits and hospitalizations each year, with respiratory infections and sexually transmitted infections being prevalent. Cancer is a leading cause of death globally, with Europe reporting over 1.9 million cancer-related deaths annually. In the USA, cancer is the second leading cause of death, accounting for nearly 600,000 fatalities annually. Autoimmune diseases affect millions of people worldwide, with rheumatoid arthritis and multiple sclerosis being prevalent in Europe and the USA.

The growth of the immunostimulant market is driven by factors such as the increasing prevalence of infectious diseases and cancer, advancements in biotechnology and immunology research, and the growing demand for personalized medicine. Companies such as GSK, Sanofi, National Institute of Allergy and Infectious Diseases, Moderna, Pfizer, Merck (MSD), BioNTech, Inovio, CSL Behring, J&J, Takeda, University of Oxford, Bavarian Nordic, Emergent Biosolutions, AstraZeneca, Grifols, National Cancer Institute, Sinovac, Serum Institute of India, GC Biopharma, ImmunityBio, Sinopharm, CureVac, Dynavax, Boehringer Ingelheim, Roche cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, GSK is currently conducting a clinical trial of Omipalisib (GSK2126458) for treating idiopathic pulmonary fibrosis.

Key Developments:

  • In April 2023, the Therapeutic Goods Administration (TGA) provided full registration for Moderna’s Elasomeran in COVID-19 infections.
  • In Feb 2022, GSK’s Rotarix was registered for rotavirus infections (In infants, Prevention) in the USA.

Approved Immunostimulant Molecules

  • Comirnaty (tozinameran)
  • Zyclara (imiquimod)
  • Engerix-B (hepatitis B vaccine recombinant)
  • Fluzone (influenza vaccine)
  • Spikevax (elasomeran)
  • Rotarix (rotavirus vaccine)
  • FluMist Quadrivalent (live attenuated influenza vaccine nasal spray)
  • CoronaVac
  • Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine)
  • Fluarix (influenza virus trivalent vaccine)
  • Cervarix (recombinant human papillomavirus bivalent vaccine)
  • Vaxigrip (inactivated influenza vaccine (split virion))
  • FluMist (influenza vaccine, live, intranasal)
  • Havrix (hepatitis A vaccine, inactivated)
  • Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine)
  • Shingrix (zoster vaccine recombinant adjuvanted)
  • Fluzone High-Dose Quadrivalent (influenza vaccine)
  • Zostavax (zoster vaccine live)
  • Imlygic (talimogene laherparepvec)
  • Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate)
  • Bexsero (meningococcal group B vaccine)
  • TicoVac (tick-borne encephalitis vaccine, whole Virus inactivated)
  • Fluarix Quadrivalent (influenza vaccine)
  • Ontak (denileukin diftitox)
  • RotaTeq (Live attenuated pentavalent Rotavirus oral vaccine)
  • ALVAC-HIV
  • FLUAD (trivalent inactivated influenza vaccine)
  • Provenge (sipuleucel-T)
  • Dengvaxia (Dengue vaccine)
  • Mosquirix (RTS,S)
  • Rabavert (purified chicken-embryo cell rabies vaccine)
  • Reolysin (pelareorep)
  • JYNNEOS (live modified vaccinia virus ankara)
  • Measles vaccine
  • BBIBP-CorV

Immunostimulant Pipeline Molecules

  • ACAM2000 (smallpox (vaccinia) live vaccine)
  • Mos4.HIV
  • ACI-7104
  • AGS-004
  • ABNCoV2
  • AD01
  • AE 37
  • AG0302-COVID19
  • ABO1009-DP
  • ADM03820
  • Adintrevimab (ADG20)
  • 7HP349
  • 800 TCR
  • A244
  • AAHI-SC2 Vaccine
  • AAHI-SC3 Vaccine
  • ABBV-2B04
  • ABO-CoV.617.2
  • ABO1020
  • ACI-35.030
  • ACIT-1
  • ACM-001
  • ACT 2001
  • ADU-623
  • ADXS-504
  • AG0301-COVID19
  • AIM-001

Clinical Activity and Development of Immunostimulant

In the Immunostimulant space, more than 20 companies are conducting more than 500 clinical trials in this category of drugs. For instance,

  • In October 2021, the University of Alabama completed the phase II trial of Gardasil in Human-papillomavirus-infections (In children, In adolescents, In adults, and Prevention) in the USA
  • In June 2023, Pfizer initiated a phase II trial of Comirnaty for Respiratory tract infections (Prevention, In the elderly) in the USA

Product Name

Total Studies

ACAM2000 (smallpox (vaccinia) live vaccine)

8

Ad26.Mos4.HIV

8

ACI-7104

6

AGS-004

5

ABNCoV2

3

AD01

3

AE 37

3

AG0302-COVID19

3

ABO1009-DP

2

ADM03820

2

Adintrevimab (ADG20)

2

                       

Target Indication Analysis of Immunostimulant

Immunostimulants are targeted toward a range of indications, including infectious diseases, cancer, and autoimmune disorders. These therapies aim to enhance the immune system's response, promoting the production and activity of immune cells and molecules. In infectious diseases, immunostimulants can help boost the body's natural defenses against pathogens. In cancer, they can stimulate the immune system to recognize and attack cancer cells. For autoimmune disorders, immunostimulants regulate immune responses and restore immune balance. By targeting these indications, immunostimulants hold the potential for improving patient outcomes and expanding treatment options in various disease settings.

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

Frequently Asked Questions

Immunostimulant drugs are used in the management of infectious diseases, cancer, and autoimmune disorders.

The market is primarily driven by factors such as a high prevalence of infectious diseases, a rising incidence of cancer, and an increasing demand for personalized medicine.

The major players in this space are GSK, Sanofi, National Institute of Allergy and Infectious Diseases, Moderna, Pfizer, Merck (MSD), BioNTech, Inovio, CSL Behring, J&J, Takeda, University of Oxford, Bavarian Nordic, Emergent Biosolutions, AstraZeneca, Grifols, National Cancer Institute, Sinovac, Serum Institute of India, GC Biopharma, ImmunityBio, Sinopharm, CureVac, Dynavax, Boehringer Ingelheim, Roche.

The immunostimulant market faces restraints such as stringent regulatory requirements and safety concerns associated with the use of immunostimulant drugs, limiting their widespread adoption and market growth. Additionally, the high cost of immunostimulant therapies poses a challenge for patients and healthcare systems, impacting accessibility and affordability.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

Key Market Players

  • GSK
  • Sanofi
  • Moderna
  • Pfizer
  • Merck (MSD)
  • BioNTech
  • Inovio
  • CSL Behring
  • J&J
  • Takeda
  • Bavarian Nordic
  • Emergent Biosolutions
  • AstraZeneca
  • Grifols
  • Sinovac
  • Serum Institute of India
  • GC Biopharma
  • ImmunityBio
  • Sinopharm
  • CureVac
  • Dynavax
  • Boehringer Ingelheim
  • Roche
  • Walvax
  • Gritstone bio
  • BMS
  • Fosun Pharma
  • VBI Vaccines
  • CanSino
  • Chongqing Zhifei
  • Valneva
  • Novavax

Related Industry Reports